

Huntington's Disease Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035

<https://marketpublishers.com/r/H352FCBF56B0EN.html>

Date: June 2026

Pages: 0

Price: US\$ 4,900.00 (Single User License)

ID: H352FCBF56B0EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of \$500. Please email us at order@marketpublishers.com with your request.

This report will be delivered in 7-10 working days.

Global Huntington's Disease Market, Analysis and Forecast: 2025-2035

Huntington's disease (HD) is a rare, inherited neurodegenerative disorder caused by a genetic mutation in the HTT gene, which leads to the progressive breakdown of nerve cells in the brain. The disease is characterized by motor dysfunction, cognitive decline, and psychiatric symptoms. HD typically manifests in mid-adulthood, with symptoms gradually worsening over time. The disease can lead to significant disability and death, often within 10 to 30 years of diagnosis. Diagnosis of HD is confirmed through genetic testing, and there are currently no cure options, with treatments aimed at managing symptoms. The Huntington's disease market is growing due to advancements in treatment options, improved diagnostic technologies, and increased patient awareness.

The HD market is primarily driven by the increasing prevalence of the disease, along with advances in genetic testing and imaging techniques that enable earlier and more accurate detection. The growing aging population, which is more susceptible to neurodegenerative disorders, and improved access to healthcare are also contributing to the demand for treatments. Moreover, the approval of novel therapies, such as gene therapies and disease-modifying treatments, is driving market expansion. These therapies offer potential solutions for both motor and cognitive symptoms, addressing a significant unmet need in the market. Furthermore, continuous investment in research

and development, supported by both public and private sectors, is accelerating the discovery of new treatment modalities and biomarkers, contributing to the ongoing market growth.

The huntington's disease market faces several challenges, including the high cost of novel therapies, such as gene therapies and gene-silencing treatments, which may limit patient access, particularly in low- and middle-income regions with constrained healthcare budgets. Additionally, the rarity of the disease and the complexity of its management result in limited awareness and expertise, often leading to delayed diagnoses. Furthermore, the treatment landscape for Huntington's disease is evolving, with no universally accepted treatment protocols in place, making the management of the disease challenging. Regulatory hurdles also pose a challenge, as the approval process for novel therapies can be lengthy, delaying patient access to new and potentially life-saving treatments.

Recent advancements in huntington's disease treatment have introduced new therapeutic options, including gene therapies such as AMT-130, which aims to address the root cause of the disease by targeting the mutant huntingtin gene. Additionally, antisense oligonucleotides, such as tominersen, are being explored to reduce the production of the mutant protein and slow disease progression. Symptomatic treatments, such as the use of tetrabenazine for chorea and antipsychotic medications for psychiatric symptoms, are also commonly employed. Moreover, several new investigational therapies, including gene-silencing therapies and neuroprotective agents, are showing promise, with clinical trials underway to explore their effectiveness in modifying disease progression.

The competitive landscape in the huntington's disease market is evolving, with major pharmaceutical companies such as Prilenia Therapeutics B.V., Novartis AG, and Bausch Health Companies Inc. leading the way with approved treatments and novel therapies. Additionally, several emerging biotech companies are focusing on developing next-generation therapies, including gene-silencing treatments and neuroprotective therapies. Collaborations between pharmaceutical companies, research institutions, and healthcare providers are becoming more common, with a shared focus on advancing personalized medicine and improving treatment outcomes for huntington's disease patients.

Market Segmentation:

Segmentation 1: by Drug Class

Antidepressants

Antipsychotic Drugs

Deutetrabenazine

Deutetrabenazine

RNA-based Therapy

Tetrabenazine

Segmentation 2: by the Region

North America

Europe

Asia-Pacific

Rest-of-the-World

The global huntington's disease (HD) market is experiencing steady growth, driven by several key factors. Firstly, the increasing prevalence of Huntington's disease, particularly in aging populations, has led to a heightened demand for effective treatment solutions. Secondly, advancements in diagnostic technologies, such as genetic testing and improved imaging techniques, have enabled earlier and more accurate detection of HD, leading to better patient outcomes. Thirdly, the approval and introduction of novel therapies, including gene therapies and disease-modifying treatments, have expanded treatment options, offering more targeted and effective solutions for managing both the motor and cognitive symptoms of the disease. Additionally, rising awareness among healthcare professionals and patients has led to more diagnoses, increasing the need for specialized therapies. Furthermore, the growing investment in research and development, supported by both public and private sectors, is accelerating the discovery of new therapeutic modalities and biomarkers, contributing to the ongoing market growth.

Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note

1. GLOBAL HUNTINGTON'S DISEASE MARKET: INDUSTRY ANALYSIS

1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
 1.3.1 Impact Analysis
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
 1.6.1 Overview
 1.6.2 Market Drivers
 1.6.3 Market Restraints
 1.6.4 Market Opportunities

2. GLOBAL HUNTINGTON'S DISEASE MARKET (BY DRUG CLASS), VALUE (\$MILLION), 2023-2035

2.1 Antidepressants
2.2 Antipsychotic Drugs
2.3 Deutetrabenazine
2.4 Gene Therapy
2.5 RNA-based Therapy
2.6 Tetrabenazine

3. GLOBAL HUNTINGTON'S DISEASE MARKET (BY REGION), VALUE (\$MILLION), 2023-2035

3.1 North America
 3.1.1 Market Dynamics
 3.1.2 Market Sizing and Forecast

3.1.3 North America Huntington's Disease Market, by Country (\$Million), 2023-2035

3.1.3.1 U.S.

3.1.3.2 Canada

3.2 Europe

3.2.1 Market Dynamics

3.2.2 Market Sizing and Forecast

3.2.3 Europe Huntington's Disease Market, by Country (\$Million), 2023-2035

3.2.3.1 U.K.

3.2.3.2 France

3.2.3.3 Germany

3.2.3.4 Italy

3.2.3.5 Spain

3.2.3.6 Rest-of-Europe

3.3 Asia-Pacific

3.3.1 Market Dynamics

3.3.2 Market Sizing and Forecast

3.3.3 Asia-Pacific Huntington's Disease Market, by Country (\$Million), 2023-2035

3.3.3.1 Japan

3.3.3.2 China

3.3.3.3 India

3.3.3.4 Australia

3.3.3.5 South Korea

3.3.3.6 Rest-of-Asia-Pacific

3.4 Rest-of-the-World

3.4.1 Market Dynamics

3.4.2 Market Sizing and Forecast

3.4.3 Rest-of-the-World Huntington's Disease Market, by Country (\$Million), 2023-2035

3.4.3.1 Latin America

3.4.3.2 Middle East and Africa

4. COMPETITIVE LANDSCAPE AND COMPANY PROFILES

4.1 Competitive Landscape

4.1.1 Mergers and Acquisitions

4.1.2 Partnership, Alliances and Business Expansion

4.1.3 New Offerings

4.1.4 Regulatory Activities

4.1.5 Funding Activities

4.2 Company Profiles

4.2.1 Alnylam Pharmaceuticals, Inc.

4.2.1.1 Overview

4.2.1.2 Top Products / Product Portfolio

4.2.1.3 Top Competitors

4.2.1.4 Target Customers/End-Users

4.2.1.5 Key Personnel

4.2.1.6 Analyst View

4.2.2 Bausch Health Companies Inc.

4.2.2.1 Overview

4.2.2.2 Top Products / Product Portfolio

4.2.2.3 Top Competitors

4.2.2.4 Target Customers/End-Users

4.2.2.5 Key Personnel

4.2.2.6 Analyst View

4.2.3 H. Lundbeck A/S

4.2.3.1 Overview

4.2.3.2 Top Products / Product Portfolio

4.2.3.3 Top Competitors

4.2.3.4 Target Customers/End-Users

4.2.3.5 Key Personnel

4.2.3.6 Analyst View

4.2.4 Hikma Pharmaceuticals PLC

4.2.4.1 Overview

4.2.4.2 Top Products / Product Portfolio

4.2.4.3 Top Competitors

4.2.4.4 Target Customers/End-Users

4.2.4.5 Key Personnel

4.2.4.6 Analyst View

4.2.5 Lupin

4.2.5.1 Overview

4.2.5.2 Top Products / Product Portfolio

4.2.5.3 Top Competitors

4.2.5.4 Target Customers/End-Users

4.2.5.5 Key Personnel

4.2.5.6 Analyst View

4.2.6 Novartis AG

4.2.6.1 Overview

4.2.6.2 Top Products / Product Portfolio

- 4.2.6.3 Top Competitors
- 4.2.6.4 Target Customers/End-Users
- 4.2.6.5 Key Personnel
- 4.2.6.6 Analyst View
- 4.2.7 Prilenia Therapeutics B.V.
 - 4.2.7.1 Overview
 - 4.2.7.2 Top Products / Product Portfolio
 - 4.2.7.3 Top Competitors
 - 4.2.7.4 Target Customers/End-Users
 - 4.2.7.5 Key Personnel
 - 4.2.7.6 Analyst View
- 4.2.8 Sun Pharmaceutical Industries, Inc.
 - 4.2.8.1 Overview
 - 4.2.8.2 Top Products / Product Portfolio
 - 4.2.8.3 Top Competitors
 - 4.2.8.4 Target Customers/End-Users
 - 4.2.8.5 Key Personnel
 - 4.2.8.6 Analyst View
- 4.2.9 Teva Pharmaceuticals Industries
 - 4.2.9.1 Overview
 - 4.2.9.2 Top Products / Product Portfolio
 - 4.2.9.3 Top Competitors
 - 4.2.9.4 Target Customers/End-Users
 - 4.2.9.5 Key Personnel
 - 4.2.9.6 Analyst View
- 4.2.10 uniQure N.V.
 - 4.2.10.1 Overview
 - 4.2.10.2 Top Products / Product Portfolio
 - 4.2.10.3 Top Competitors
 - 4.2.10.4 Target Customers/End-Users
 - 4.2.10.5 Key Personnel
 - 4.2.10.6 Analyst View
- 4.2.11 Others

5. RESEARCH METHODOLOGY

List Of Figures

LIST OF FIGURES

Figure: Global Huntington's Disease Market Coverage

Figure: Global Huntington's Disease Market Key Trends, Impact Analysis, 2023-2035

List Of Tables

LIST OF TABLES

Table: Global Huntington's Disease Market (by Drug Class), \$Million, 2023-2035

Table: Global Huntington's Disease Market (by Region), \$Million, 2023-2035

I would like to order

Product name: Huntington's Disease Market - A Global and Regional Analysis: Focus on Drug Class and Region - Analysis and Forecast, 2025-2035

Product link: <https://marketpublishers.com/r/H352FCBF56B0EN.html>

Price: US\$ 4,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H352FCBF56B0EN.html>